Salisbury Foundation Trust

FOI_5104

Internal Reference Number: FOI_5104

Date Request Received: 13/06/2019 13:48:25

Date Request Replied To: 11/07/2019 08:29:05

This response was sent via: By Email

Request Summary: Cancer services at the Trust

Request Category: Companies

 
Question Number 1:
Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
 
Answer To Question 1:
yes
 
Question Number 2:
If yes, then how many MM patients, have been treated in the past 6 months with the following;
• Bortezomib [Velcade]
• Carfilzomib [Kyprolis]
• Ixazomib [Ninlaro]
• Lenalidomide [Revlimid]
• Daratumumab [Darzalex]
• Melphalan, prednisolone and thalidomide (known as MPT)
• Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
• Pomalidomide [Imnovid]
 
Answer To Question 2:
. Bortezomib [Velcade]13 (9 first line, <5 second line)
. Carfilzomib [Kyprolis]<5(first line)
. Ixazomib [Ninlaro]5
. Lenalidomide [Revlimid]9(<5 first line, <5 unknown)
. Daratumumab [Darzalex]5 (<5 first line)
. Melphalan, prednisolone and thalidomide (known as MPT)0
. Cyclophosphamide, thalidomide and dexamethasone (known as CTD)7(split between first line and second line)
. Pomalidomide [Imnovid] <5

Please note that it is Trust policy not to disclose potentially patient identifiable information, thus if there are less than 5 patients we will specify only '<5'.
 
Question Number 3:
If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.
 
Answer To Question 3:
see above
 
Question Number 4:
Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which.
 
Answer To Question 4:
Yes, both adult and paediatric ITP
 
Question Number 5:
If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;
• Eltrombopag [Revolade]
• Romiplostim [Nplate]
 
Answer To Question 5:
. Eltrombopag [Revolade] <5
. Romiplostim [Nplate]<5
 
Question Number 6:
At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.
• 1st
• 2nd
• 3rd
• 4th
• Unknown
 
Answer To Question 6:
. Unknown Depends on the patient
 
Question Number 7:
Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?

7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
• Eltrombopag [Revolade]
• Romiplostim [Nplate]

7b.Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation
• Eltrombopag [Revolade]
• Romiplostim [Nplate]

7c. Chemotherapy induced thrombocytopenia (CIT)
• Eltrombopag [Revolade]
• Romiplostim [Nplate]
• 7d myelodysplastic syndromes (MDS)
• Eltrombopag [Revolade]
• Romiplostim [Nplate]
 
Answer To Question 7:
a) Not in recent years
b) Only in the past using an IFR, not sure which drug
c) Chemotherapy induced thrombocytopenia (CIT)No
. Eltrombopag [Revolade]
. Romiplostim [Nplate]
d) myelodysplastic syndromes (MDS)No
. Eltrombopag [Revolade]
. Romiplostim [Nplate]
 
Question Number 8:
Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated
 
Answer To Question 8:
18
 
Question Number 9:
If possible how many CLL patients treated were new to therapy in the past 3 months?
 
Answer To Question 9:
5
 
Question Number 10:
How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
• Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
• Bendamustine and rituximab (known as BR)
• Ibrutinib [Imbruvica]
• Chlorambucil
• Venetoclax
• Obinutuzumab
• Idelalisib
• Fludarabine and rituximab (known as FR)
• High-dose prednisone and rituximab
• Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
• Alemtuzumab (Campath) with rituximab
 
Answer To Question 10:
. Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)0
. Bendamustine and rituximab (known as BR)0
. Ibrutinib [Imbruvica]8
. Chlorambucil7
. Venetoclax <5
. Obinutuzumab 5
. Idelalisib <5
. Fludarabine and rituximab (known as FR)0
. High-dose prednisone and rituximab0
. Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)0
. Alemtuzumab (Campath) with rituximab0

 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values